Ładuje się......
The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development
As the first clinical proteasome inhibitor, Bortezomib (BTZ) has been reported to improve the outcome of lymphoma. However, due to the unstable property, low bioavailability, and hydrophobic properties of BTZ, it is needed to develop effective drug delivery systems to deliver BTZ into targeted cells...
Zapisane w:
| Wydane w: | Aging (Albany NY) |
|---|---|
| Główni autorzy: | , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Impact Journals
2020
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7835069/ https://ncbi.nlm.nih.gov/pubmed/33290262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.202146 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|